US Allocates $590 Million to Moderna for Bird Flu Vaccine Development

The funding aims to accelerate mRNA-based vaccine research as H5N1 infections rise in animals and sporadically affect humans.

The Department of Health and Human Services (HHS) awarded $590 million to Moderna to advance its mRNA bird flu vaccine to phase 3 trials.
This funding builds on $176 million previously granted in 2023 to develop vaccines targeting H5N1 and H7N9 strains of avian influenza.
HHS emphasizes mRNA technology for its speed and adaptability, which could provide faster responses to emerging threats compared to traditional vaccine methods.
The Centers for Disease Control and Prevention (CDC) states the general public's risk remains low, as most human cases have been linked to direct contact with infected animals.
The Biden administration is also investing over $300 million in broader bird flu preparedness, including surveillance, testing, and hospital readiness.